Interestingly, we have found that inhibition of glutamine pathway enhances the sensitivity of TIGAR overexpressing ESCC cells towards cytotoxic anticancer agents, 5FU/DDP, suggesting that a combination of glutamine pathway inhibitors and conventional cytotoxic agents may be a promising novel treatment option for ESCC with TIGAR overexpression. Here, TIGAR is linked to esophageal squamous cell carcinoma.